Protectivity of COVID-19 Vaccines and Its Relationship with Humoral Immune Response and Vaccination Strategy: A One-Year Cohort Study
This prospective cohort study aimed to evaluate the efficacy of COVID-19 vaccine schemes, homologous versus heterologous vaccine strategies, and vaccine-induced anti-S-RBD-IgG antibody response in preventing COVID-19 among 942 healthcare workers 1 year after vaccination with the inactivated and/or m...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/8/1177 |
| _version_ | 1797407601711906816 |
|---|---|
| author | Ferdi Tanir Burak Mete Hakan Demirhindi Ertan Kara Ersin Nazlican Gülçin Dağlıoğlu Filiz Kibar Salih Çetiner Ceren Kanat |
| author_facet | Ferdi Tanir Burak Mete Hakan Demirhindi Ertan Kara Ersin Nazlican Gülçin Dağlıoğlu Filiz Kibar Salih Çetiner Ceren Kanat |
| author_sort | Ferdi Tanir |
| collection | DOAJ |
| description | This prospective cohort study aimed to evaluate the efficacy of COVID-19 vaccine schemes, homologous versus heterologous vaccine strategies, and vaccine-induced anti-S-RBD-IgG antibody response in preventing COVID-19 among 942 healthcare workers 1 year after vaccination with the inactivated and/or mRNA vaccines. All participants received the first two primary doses of vaccines, 13.6% of them lacked dose 3, 50.5% dose 4, and 90.3% dose 5. Antibody levels increased with the increase in number of vaccine doses and also in heterologous vaccine regimens. In both inactive, mRNA vaccines and mixed vaccination, infection rates were significantly higher in two-dose-receivers, but lower in four- or five-dose receivers and increasing the total number of vaccine doses resulted in more protection against infection: the three-dose regimen yielded 3.67 times more protection, the four-dose 8 times, and five-dose 27.77 times more protection from COVID-19 infection, compared to any two-dose vaccination regimens. Antibody levels at the end of the first year of four- or five-dose-receivers were significantly higher than two- or three-dose receivers. To conclude, an increased number of total vaccine doses and anti-S-RBD antibody levels increased the protection from COVID-19 infection. Therefore, four or more doses are recommended in 1 year for effective protection, especially in risk groups. |
| first_indexed | 2024-03-09T03:43:55Z |
| format | Article |
| id | doaj.art-eb463d16208b4bbfb66aecda12fc8117 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T03:43:55Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-eb463d16208b4bbfb66aecda12fc81172023-12-03T14:36:26ZengMDPI AGVaccines2076-393X2022-07-01108117710.3390/vaccines10081177Protectivity of COVID-19 Vaccines and Its Relationship with Humoral Immune Response and Vaccination Strategy: A One-Year Cohort StudyFerdi Tanir0Burak Mete1Hakan Demirhindi2Ertan Kara3Ersin Nazlican4Gülçin Dağlıoğlu5Filiz Kibar6Salih Çetiner7Ceren Kanat8Department of Public Health, Faculty of Medicine, Çukurova University, Adana 01330, TurkeyDepartment of Public Health, Faculty of Medicine, Çukurova University, Adana 01330, TurkeyDepartment of Public Health, Faculty of Medicine, Çukurova University, Adana 01330, TurkeyDepartment of Public Health, Faculty of Medicine, Çukurova University, Adana 01330, TurkeyDepartment of Public Health, Faculty of Medicine, Çukurova University, Adana 01330, TurkeyCentral Laboratory, Balcalı Hospital, Faculty of Medicine, Çukurova University, Adana 01330, TurkeyCentral Laboratory, Balcalı Hospital, Faculty of Medicine, Çukurova University, Adana 01330, TurkeyCentral Laboratory, Balcalı Hospital, Faculty of Medicine, Çukurova University, Adana 01330, TurkeyDepartment of Public Health, Faculty of Medicine, Çukurova University, Adana 01330, TurkeyThis prospective cohort study aimed to evaluate the efficacy of COVID-19 vaccine schemes, homologous versus heterologous vaccine strategies, and vaccine-induced anti-S-RBD-IgG antibody response in preventing COVID-19 among 942 healthcare workers 1 year after vaccination with the inactivated and/or mRNA vaccines. All participants received the first two primary doses of vaccines, 13.6% of them lacked dose 3, 50.5% dose 4, and 90.3% dose 5. Antibody levels increased with the increase in number of vaccine doses and also in heterologous vaccine regimens. In both inactive, mRNA vaccines and mixed vaccination, infection rates were significantly higher in two-dose-receivers, but lower in four- or five-dose receivers and increasing the total number of vaccine doses resulted in more protection against infection: the three-dose regimen yielded 3.67 times more protection, the four-dose 8 times, and five-dose 27.77 times more protection from COVID-19 infection, compared to any two-dose vaccination regimens. Antibody levels at the end of the first year of four- or five-dose-receivers were significantly higher than two- or three-dose receivers. To conclude, an increased number of total vaccine doses and anti-S-RBD antibody levels increased the protection from COVID-19 infection. Therefore, four or more doses are recommended in 1 year for effective protection, especially in risk groups.https://www.mdpi.com/2076-393X/10/8/1177SARS-CoV-2inactivated vaccinemRNA vaccineCOVID-19homologous vaccinationheterologous vaccination |
| spellingShingle | Ferdi Tanir Burak Mete Hakan Demirhindi Ertan Kara Ersin Nazlican Gülçin Dağlıoğlu Filiz Kibar Salih Çetiner Ceren Kanat Protectivity of COVID-19 Vaccines and Its Relationship with Humoral Immune Response and Vaccination Strategy: A One-Year Cohort Study Vaccines SARS-CoV-2 inactivated vaccine mRNA vaccine COVID-19 homologous vaccination heterologous vaccination |
| title | Protectivity of COVID-19 Vaccines and Its Relationship with Humoral Immune Response and Vaccination Strategy: A One-Year Cohort Study |
| title_full | Protectivity of COVID-19 Vaccines and Its Relationship with Humoral Immune Response and Vaccination Strategy: A One-Year Cohort Study |
| title_fullStr | Protectivity of COVID-19 Vaccines and Its Relationship with Humoral Immune Response and Vaccination Strategy: A One-Year Cohort Study |
| title_full_unstemmed | Protectivity of COVID-19 Vaccines and Its Relationship with Humoral Immune Response and Vaccination Strategy: A One-Year Cohort Study |
| title_short | Protectivity of COVID-19 Vaccines and Its Relationship with Humoral Immune Response and Vaccination Strategy: A One-Year Cohort Study |
| title_sort | protectivity of covid 19 vaccines and its relationship with humoral immune response and vaccination strategy a one year cohort study |
| topic | SARS-CoV-2 inactivated vaccine mRNA vaccine COVID-19 homologous vaccination heterologous vaccination |
| url | https://www.mdpi.com/2076-393X/10/8/1177 |
| work_keys_str_mv | AT ferditanir protectivityofcovid19vaccinesanditsrelationshipwithhumoralimmuneresponseandvaccinationstrategyaoneyearcohortstudy AT burakmete protectivityofcovid19vaccinesanditsrelationshipwithhumoralimmuneresponseandvaccinationstrategyaoneyearcohortstudy AT hakandemirhindi protectivityofcovid19vaccinesanditsrelationshipwithhumoralimmuneresponseandvaccinationstrategyaoneyearcohortstudy AT ertankara protectivityofcovid19vaccinesanditsrelationshipwithhumoralimmuneresponseandvaccinationstrategyaoneyearcohortstudy AT ersinnazlican protectivityofcovid19vaccinesanditsrelationshipwithhumoralimmuneresponseandvaccinationstrategyaoneyearcohortstudy AT gulcindaglıoglu protectivityofcovid19vaccinesanditsrelationshipwithhumoralimmuneresponseandvaccinationstrategyaoneyearcohortstudy AT filizkibar protectivityofcovid19vaccinesanditsrelationshipwithhumoralimmuneresponseandvaccinationstrategyaoneyearcohortstudy AT salihcetiner protectivityofcovid19vaccinesanditsrelationshipwithhumoralimmuneresponseandvaccinationstrategyaoneyearcohortstudy AT cerenkanat protectivityofcovid19vaccinesanditsrelationshipwithhumoralimmuneresponseandvaccinationstrategyaoneyearcohortstudy |